• About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
Shopping cart close
Scilex Holding Scilex Holding
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations

Posts by Ulisses

Home » Articles Posted by Ulisses (Page 10)
15 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 15, 2023
  • Posted by Ulisses

Read more

15 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 15, 2023
  • Posted by Ulisses

Read more

15 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 15, 2023
  • Posted by Ulisses

Read more

13 Feb
SEC FIlings

Current report

  • February 13, 2023
  • Posted by Ulisses

Read more

13 Feb
Press Release

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

  • February 13, 2023
  • Posted by Ulisses
Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for...

Read more

13 Feb
SEC FIlings

Statement of acquisition of beneficial ownership

  • February 13, 2023
  • Posted by Ulisses

Read more

12 Feb
Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYBTM in the U.S. and Canada for the acute treatment of migraine

  • February 12, 2023
  • Posted by Ulisses
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1   The acute migraine drug market size...

Read more

09 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 9, 2023
  • Posted by Ulisses

Read more

09 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 9, 2023
  • Posted by Ulisses

Read more

09 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 9, 2023
  • Posted by Ulisses

Read more

«‹89101112›»
Close
Recent Posts
  • scilex-no-pic
    Henry Ji, PhD
    August 21, 2025 No Comments
  • scilex-no-pic
    Stephen Ma
    August 21, 2025 No Comments
  • scilex-no-pic
    Dorman Followwill 
    August 21, 2025 No Comments
  • Alexander Wu, PhD
    August 21, 2025 No Comments
  • scilex-no-pic
    Jay Chun, MD, PhD
    August 21, 2025 No Comments
scilex-holding-logo-white

Terms of Use  Privacy Policy  Contact

  • Follow us on Facebook
  • Follow us on LinkedIn
  • Contact us by email

©2025 Scilex Holding All Rights Reserved
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

  • <
  • <
  • <
Scroll To Top Sidebar
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Accept More info